Shares of enGene Holdings Inc. (NASDAQ:ENGNW – Get Free Report) were up 3.3% on Friday . The stock traded as high as $0.29 and last traded at $0.2890. 501 shares changed hands during trading, a decline of 97% from the average daily volume of 18,241 shares. The stock had previously closed at $0.2798.
enGene Stock Performance
The company’s 50-day moving average is $0.77 and its 200-day moving average is $2.12.
enGene Company Profile
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Featured Stories
- Five stocks we like better than enGene
- Capri’s Turnaround Is Taking Shape, But Is the Stock a Buy Yet?
- SpaceX Has Real Value—But These 3 Stocks Have Better Odds Right Now
- 3 Stocks That Could Benefit as the Robotaxi Race Heats Up
- 3 Waste Stocks Turning AI Investments into Growth
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.
